Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Ovarian Neoplasms 3Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation 1Pancreatic Neoplasms 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Fludzoparib" and Anti-angiogenic 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1Breast Cancer Metastatic 1

Interventions

fluzoparib 1exemestane 1dalpiciclib 1Trastuzumab 1Letrozole 1Ga(III)-DOTATOC 1Everolimus 1Docetaxel 1Aromatase Inhibitors 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Breast Cancer Metastatic × fluzoparib × Clear all
NCT06612814 2024-09-25

PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Fudan University

Phase 3 Active not recruiting
307 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡